Amgen AMGN Other products — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amgen in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Amgen’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amgen's other products — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amgen's other products — total revenues?
- Amgen (AMGN) reported other products — total revenues of $1.53B in Q1 2026.
- How has Amgen's other products — total revenues changed year-over-year?
- Amgen's other products — total revenues increased by 3.6% year-over-year, from $1.48B to $1.53B.
- What is the long-term trend for Amgen's other products — total revenues?
- Over 4 years (2021 to 2025), Amgen's other products — total revenues has grown at a 5.6% compound annual growth rate (CAGR), from $5.71B to $7.09B.
- What does other products — total revenues mean?
- This metric represents the aggregate gross revenue generated from the company's portfolio of secondary or non-core therapeutic products that do not fall into the primary flagship product categories. It captures the financial performance of smaller-scale, legacy, or emerging assets within the biotechnology segment. Monitoring this revenue stream helps assess the diversification of the product pipeline and the contribution of secondary assets to overall top-line growth.